Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children (Q45256524)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 November 2011

Language	Label	Description	Also known as
English	Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children	scientific article published on 6 November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

object named as

M Rheeders

6

0 references

author name string

M Viljoen

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

M O Karlsson

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

T M Meyers

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

H Gous

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

publication date

6 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

68

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

339-347

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Therapeutic drug monitoring in children with HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Pharmacokinetics of antiretroviral therapy in HIV-1-infected children

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Antiretroviral pharmacokinetics in the paediatric population: a review

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Efavirenz liquid formulation in human immunodeficiency virus-infected children

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Pharmacogenetics of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Successful genotype-tailored treatment with small-dose efavirenz

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

A size standard for pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1148-7

21 January 2018

Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetic meta-analysis with efavirenz

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence to antiretroviral therapy: how much is enough?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/22057858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-011-1148-7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45256524&oldid=2207176528"